Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy

Management strategies and clinical outcomes in breast cancer patients who develop left ventricular dysfunction during trastuzumab therapy

Abstract Background Trastuzumab reduces risk of breast cancer recurrence but carries risk of cardiotoxicity that may be reversible upon treatment cessation and institution of left ventricular (LV) enhancement therapies (LVETx). We assessed management patterns of trastuzumab-induced cardiotoxicity (T...

Full description

Bibliographic Details
Main Authors: Ren Jie Robert Yao, Jordan Gibson, Christine Simmons, Margot K. Davis
Format: Article
Language:English
Published: BMC 2021-03-01
Series:Cardio-Oncology
Subjects:
Trastuzumab
Left ventricular dysfunction
Heart failure
Breast cancer
Online Access:https://doi.org/10.1186/s40959-021-00099-7

Internet

https://doi.org/10.1186/s40959-021-00099-7

Similar Items